Announced Thu, 21 May · 12:43 IST

Q4 & FY 26 Earnings Conference Call Transcript

Mgmt Guided Margin ImprovementCfo Debt Reduction RoadmapInvestor Communications View source PDF

JLHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.9%1-day move
₹1321.00
prior close
₹1321.80
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.1+0.0-0.0+2.9+2.8+0.8+0.3+0.4+1.4-0.2+1.5+18.7
Up moveDown movePending
AI summary

Jupiter Life Line Hospitals reported FY26 total income of INR1,499.8 crore (up 15.2% YoY) with EBITDA of INR343.3 crore (22.9% margin) and PAT of INR194.2 crore. Q4 revenue was INR387.8 crore with 23% EBITDA margin. The newly commissioned Dombivli hospital (opened February 2026, 2 months ahead of schedule) is in early ramp-up with insurance empanelment expected in 6-12 months and EBITDA breakeven targeted in 2 years (monthly burn of INR2-3 crore). The expansion pipeline includes Dombivli (500 beds), Pune South (CY28), Mira Road (regulatory stage), and a 400-bed BKC facility. Management confirmed capex for ~1,700 beds at ~INR1.5 crore per bed, funded by internal accruals and debt capped at 3x EBITDA. Thane occupancy is ~75%, Pune ~65%, and Indore ~45-50%.

Likely market impact

Jupiter delivered strong full-year growth with margin expansion driven by ARPOB improvement (+11.7% to INR67,700) and better case mix. The expansion roadmap to ~3,000 beds is fully funded through internal accruals, keeping balance sheet risk manageable despite significant capex deployment.